Psoriasis News Archive

Alternative Medicines May Aid in the Treatment of Psoriasis

Most studies evaluated fish oil, acupuncture, indigo naturalis, curcumin, meditation.

Psoriasis Treatment With Biologics Often Requires Multiple Courses, Treatment Changes

The final analysis set comprised biologic-naïve individuals — individuals who had filled an initial prescription for etanercept, infliximab, adalimumab, or ustekinumab after 2 years without using any biologic agent during the study period.

Comorbidity risks increase in children with psoriasis

Some of the comorbidities include increased lipid levels, hypertension, and diabetes.

Methotrexate vs tumor necrosis factor inhibitors for pediatric psoriasis

Medication-related adverse events occur more frequently with methotrexate in children with moderate to severe psoriasis.

Severe psoriasis linked to higher mortality risk

Patients with psoriasis whose disease affects >10% of their body surface area (BSA) are at an increased risk for death compared with the general population.

Sleep disturbance in psoriasis leads to psychological and physical predictors

Sleep complaints among individuals with psoriasis warrant greater clinical attention, as they have a greater chance for developing obstructive sleep apnea.

Psoriasis patients have an increased risk of alcohol-related mortality

Patients with psoriasis have a greater risk of mortality due to alcohol-related causes, including alcoholic liver disease, fibrosis and cirrhosis of the liver, and mental and behavioral disorders.

Secukinumab well-tolerated in patients with scalp psoriasis

This study shows that more than 50% of patients can expect a 90% or greater improvement in scalp psoriasis within 12 weeks.

Smoking may be a risk factor for psoriasis

Researchers observed a positive correlation between the amount and duration of smoking and the occurrence of psoriasis.

Biosimilar ABP 501 and adalimumab safe and effective for plaque psoriasis

Biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of plaque psoriasis.

Dalazatide effective for skin lesions in plaque psoriasis

Dalazatide treatment reduced the plasma levels of multiple inflammation markers and reduced the expression of T cell activation markers on peripheral blood memory T cells.

Screening guidelines for pediatric psoriasis comorbidities

The guidelines are the first to provide recommendations for comorbidity screening in pediatric psoriasis patients.

Cardiometabolic comorbidity rates high in psoriasis patients

The most common comorbidities found in patients with psoriasis are hyperlipidemia, hypertension, depression, type 2 diabetes mellitus, and obesity.

Biologic treatment for psoriasis shows long-term effectiveness

Researchers sought to analyze long-term and real-world outcome data in patients with moderate-to-severe psoriasis after starting biologic treatment.

First-line biologic treatment for psoriasis influenced by specific factors

Presence of psoriatic arthritis, weight, employment status, baseline disease severity affect the selection of first-line biologic treatment.

High fatigue common in psoriatic arthritis

Nearly 50% of patients with psoriatic arthritis report elevated levels of fatigue.

FDA approves Inflectra biosimilar for rheumatoid arthritis, psoriasis

The biosimilar has also been approved for Crohn's disease, ulcerative colitis, and ankylosing spondylitis.

Psoriasis severity linked to work productivity, quality of life

Mild, moderate, and severe psoriasis can patients' quality of life and workplace productivity.

Patients with psoriasis have an increased risk of abdominal aortic aneurysm

Patients with psoriasis are more likely to have an abdominal aortic aneurysm, with the likelihood increasing with more severe psoriasis.

Severe psoriasis, nail pitting possible risks for development of psoriatic arthritis

Researchers found that the annual incidence rate of PsA was 2.7 cases per 100 psoriasis patients.

Brand-name, generic dermatologic drug prices increasing

Escalating prices were found across all categories of dermatologic drugs, including anti-infective medications and treatments for psoriasis and rosacea.

Economic and racial barriers impact psoriasis treatment

Only 10% of Medicare beneficiaries were receiving biologic treatments for psoriasis.

El Niño linked to rise in a range of dermatologic conditions

El Nino and La Nina have been linked to increases in actinic keratosis, rosacea, dermatitis, psoriasis, and varicella, among other dermatologic conditions.

Bariatric surgery may reduce severity of psoriasis, psoriatic arthritis

Patients with psoriasis or psoriatic arthritis who undergo bariatric surgery may see significant improvements in disease severity.

Biologic agents associated with high risk of hepatitis B virus flares in patients with psoriasis or rheumatoid arthritis

The use of biologic agents in treatment of patients rheumatoid arthritis or psoriasis is associated with a significant risk of heptatis B flares.

Combination use of methotrexate and golimumab may significantly improve psoriatic arthritis symptoms

Using methotrexate and golimumab in combination may significantly improve some symptoms among patients diagnoes with psoriatic arthritis.

Golimumab reduces symptom severity, improves disease outcome in psoriatic arthritis

Several controlled clinical trials have proven the efficacy of golimumab in reducing symptom severity and improving disease outcomes in patients with psoriatic arthritis.

Public misconceptions about psoriasis contribute to its stigma

Many people think that psoriasis is contagious or that it is caused by an infection, which contribute to the stigma.

More severe psoriasis increases vascular inflammation levels

The most severe cases of psoriasis can increase vascular inflammation levels by as much as 41%.

More evidence shows association between psoriasis, depression

Another study linked psoriasis to major depression, but the results still do not show a causal effect.

Brodalumab, secukinumab show efficacy for psoriasis treatment

Two studies indicate that brodalumab and secukinumab had significant benefits for patients with psoriasis or psoriatic arthritis.

Increased risk for arrhythmia in psoriasis patients

Patients with psoriasis, especially those with psoriatic arthritis, have an increased risk of arrhythmia.

Adding kunzea oil does not increase psoriasis treatment efficacy

Adding kunzea oil to topical psoriasis treatments did not improve their efficacy.

Biologics increase patient satisfaction in psoriasis treatment

Patients with psoriasis who take biologic medications report more overall treatment satisfaction.

Biologic medications most effective for pediatric psoriasis

The safety and efficacy of 56 treatment courses for pediatric psoriasis were evaluated.

Psoriasis increases depression risk in women

Women with psoriasis and psoriatic arthritis have an increased risk of depression.

Psoriasis drug may help preserve pancreatic function in type 1 diabetes

Alefacept, a psoriasis treatment, can help preserve pancreas function in type 1 diabetes.

Physical trauma increases psoriatic arthritis risk

Psoriasis patients exposed to trauma have an increased risk for psoriatic arthritis.

Education on psoriasis is needed for patients and clinicians

Patients and practitioners require significant education about psoriasis, including information on treatment options.

Ixekizumab quickly, effectively treats psoriasis

The monoclonal antibody ixekizumab was more effective than other treatments for treating psoriasis.

Novel drug may be effective for psoriasis

Guselkumab was more effective than standard psoriasis treatment but had higher rates of pneumonia.

New diagnosis of psoriatic arthritis predicts cardiovascular disease

People with newly diagnosed psoriatic arthritis have an increased risk of later CVD.

Psoriasis drug may also aid weight loss

Nearly 20% of patients lost more than 5% of their baseline weight by 52 weeks or less when assigned to receive apremilast.

Additional evidence of link between psoriasis, kidney disease

Patients with psoriasis should avoid long-term use of medications that are toxic to the kidneys.

Biologic therapy may be safe for hemodialysis patients with psoriasis

Patient with psoriasis were unsuccessfully treated with conventional therapies before treatment with biologics.

Psoriasis not independent risk factor for heart disease

Patients with psoriasis do not have an increased of major cardiovascular events like heart attack and stroke.

Adalimumab clears psoriasis faster than traditional treatment

Patients taking adalimumab saw quicker treatment of their psoriasis than those taking methotrexate.

Possible link between male sex hormones, psoriasis severity

Male patients with psoriasis have higher levels of estradiol and lower levels of testosterone compared with controls.

Phase 1 trial results favorable for new psoriasis drug

The rate of reported adverse events was comparable in both the treatment and placebo groups.

Obesity, hypertension, diabetes often accompany psoriasis diagnosis

It is estimated that 30% to 60% of children with juvenile psoriasis develop plaque psoriasis, according to the researchers.

Combination psoriasis treatments lack efficacy, safety information

The preferred order for combining a second modality with biologics is biologic and methotrexate combination, biologic and acitretin combination, and then biologic and phototherapy combination.

Therapeutic silencing of IL-23 may treat psoriasis

These study findings confirm that the therapeutic silencing of IL-23 is a potential target for psoriasis prevention and management.

Integrating alternative medicine, psoriasis treatment

Consistent evidence supports the use of fish oil supplementation. Zinc supplementation, however, has not been proven effective.

Sleep apnea could raise psoriasis risk in women

The presence of snoring was not associated with a higher risk of psoriasis.

Researchers identify gene that causes psoriatic arthritis

This discovery could prevent progression of psoriatic arthritis in patients with psoriasis.

Methotrexate, cyclosporine among most affordable psoriasis treatments

Infliximab and ustekinumab 90 mg were the most costly therapies.

Phase 1 trial results favorable for experimental psoriasis drug

The 31 patients who received BI 655066 had clinical improvement beginning at week 2 and maintained through week 66 weeks.

H. Pylori may affect psoriasis severity

The prevalence of H. pylori was not higher in psoriasis versus the control, but patients infected with H. pylori showed more severe psoriasis compared with uninfected patients.

Most psoriasis patients being treated accordingly

Providers may have not made changes to treatment strategies due to the high effectiveness of biologics in most visits.

Multiple dermatologic rashes complicate psoriasis diagnosis

The dermatitis patient can be extremely complex in their presentation, as well as have multiple dermatoses complicating the diagnosis.

Anti-TNF alpha drugs rarely cause lupus flares in patients with psoriasis, lupus

The coexistence of psoriasis with lupus erythematosus is rare and often presents a therapeutic challenge.

Psoriasis: When the 'usual suspect' therapy works

Topical corticosteroids and ultraviolet therapies are still proving to be strong competitors in psoriasis treatment.

Consider Achilles arthropathy in asymptomatic patients with psoriasis

The initial site of articular inflammation is where the Achilles tendon attaches to the bone.

Fumaric acid esters effective psoriasis treatment in Germany

The long-term safety profile of continuous fumaric acid esters treatment is favorable.

Psoriasis patients less likely to exercise

Less likely to engage in moderate to vigorous physical activity, especially those with severe disease

Tonsillectomy may improve psoriasis symptoms in select patients

The causative link between chronic tonsillitis and psoriasis have been mostly speculative based on translational association studies.

Secukinumab earns FDA approval for plaque psoriasis

Secukinumab has been approved by the FDA for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Education needed for cardiovascular risks linked to psoriasis, PsA

Educational programs may improve cardiovascular and metabolic risk management in patients.

Biologic monotherapy more effective combination Tx in psoriasis patients

Agents in biologic monotherapy target key processes in the pathogenesis of psoriasis, therefore offering better efficacy than current biologic and systemic therapies.

Psoriasis may cost United States $135 billion each year

Direct costs of psoriasis ranged from $51.7 billion to $63.2 billion, and indirect costs ranged from $23.9 billion to $35.4 billion.

Emphasize lifestyle behavior changes for patients with psoriasis

Clinicians who treat patients with psoriasis may need additional training in lifestyle behavior modification initiatives.

No link between psoriasis, increased herpes zoster risk

Patients with certain autoimmune diseases have a higher risk for varicella zoster infection, but the rates were not significant among patients with psoriasis.

Diet, alcohol consumption effect psoriasis symptoms

Overweight and obese psoriasis patients should to lose weight and increase physical activity as a way to improve psoriasis symptoms.

Psoriasis linked to increased chronic kidney disease, glomerulonephritis risk

The increased risk of CKD and GN was seen in patients with both mild and severe psoriasis.

A recurring, itchy, burning rash in a patient taking beta-blockers

Beta-blockers are known to induce or aggravate psoriasis and should be avoided in these patients whenever possible.

Tobacco, alcohol counseling may improve psoriasis outcomes

Provide screening and counseling to address the impact of alcohol and tobacco use in patients with psoriasis.

Nail psoriasis treatment recommendations now available

Dermatological experts developed four clinical nail psoriasis scenarios for clinicians.

Psoriasis may be linked to advanced liver fibrosis

The prevalence of advanced liver fibrosis was 8.1% in patients with psoriasis, compared with only 3.6% in the control group.

Biologics may up fungal infection risk in patients with psoriasis

The incidence of deep fungal infections has risen with the increase of biologic treatment in psoriasis patients.

Brodalumab outperforms ustekinumab for psoriasis treatment

Brodalumab completely cleared the skin of more patients with psoriasis in a 3-month period than Stelera.

Secukinumab may clear psoriasis for a year

All subjects successfully self-administered treatment at Week 1, without critical use-related hazards.

Psoriasis, psoriatic arthritis increases cardiovascular risk

Cardiovascular risk is increased in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis.

Psoriasis severity tied to increased risk for uncontrolled hypertension

An estimated 60% of study participants with psoriasis had uncontrolled hypertension.

Less stress equals better-looking skin

Research into blocking specific steps in certain pathways between the nervous system and the skin could lead to improved treatment of some skin disorders.

Sacroiliitis could be surrogate marker for CVD in psoriasis patients

Sacroiliitis predicted vascular inflammation beyond psoriatic arthritis and cardiovascular risk factors.

Cancer rates higher among patients with psoriasis

Researchers analyzed cancer rates for different psoriasis treatments, but did not find a significantly greater risk associated with any particular therapy.

Dendritic cells could be target for psoriasis therapy

Results of a recent study suggest targeting these cells may be a way to prevent and treat psoriasis.

Psoriasis patients on TNF-alpha blockers not at risk for cardiovascular disease

Treatment with TNF-alpha inhibitors demonstrated no increased risk of major cardiac events.

New psoriatic arthritis patients switch treatments often

Disease-modifying antirheumatic drug treatments are often discontinued, changed, or added-on to in patients with psoriatic arthritis.

Could nail involvement predict psoriatic arthritis?

In-patient treatment and nail involvement were the strongest predictors of future PsA.

Antidrug antibodies impact adalimumab treatment outcomes in psoriatic arthritis

Determining the ideal blood serum level could translate to improved outcomes for patients with PsA.

Cardiovascular risk factors may dictate psoriatic arthritis severity

Half of the patients in the study were newly diagnosed with four or more symptoms of metabolic syndrome.

Weight-loss benefits extend to psoriatic arthritis

Losing weight while taking biologics for psoriatic arthritis (PsA) resulted in greater symptom improvement among obese/overweight compared than no weight loss.

Genomic test differentiates between psoriasis, eczema

The test identified whether all patients in the study had either dermatologic condition correctly.

Psoriatic Arthritis Forum calls for better comorbidity screening

Rheumatologists, dermatologists, and patient representatives collaborated to draft these first-ever guidelines.

Psoriatic arthritis outcomes worse with smoking

Worse patient-reported outcomes, shorter treatment adherence, and poorer response to treatment among smokers.

Early dermatologic follow-up benefits psoriasis

Only about 20% of patients with psoriasis were seen by their health-care provider for follow up within one to two weeks after an initial visit.

Psoriasis may be triggered by nerve cells responsible for feeling pain

Researchers are investigating ways to mediate the interactions between immune cells and nerves.

Detailed screening tools help diagnose PsA

PsA prevalence based on the patient-administered screening tools was 12% to 16% higher compared with rheumatologists' diagnosis.

Newly discovered protein may be key to psoriasis Tx

AhR signaling in nonhematopoietic cells plays a pivotal role in prevention of excessive skin inflammation.

Sign Up for Free e-newsletters